Changes in carnitine levels through induction chemotherapy in head and neck cancer patients as a potential cause of therapy-related malaise

@article{Ito2021ChangesIC,
  title={Changes in carnitine levels through induction chemotherapy in head and neck cancer patients as a potential cause of therapy-related malaise},
  author={Tatsuya Ito and Kiyoaki Tsukahara and Hiroki Sato and Akira Shimizu and Isaku Okamoto},
  journal={BMC Cancer},
  year={2021},
  volume={21}
}
Background Carnitine is related to malaise, and cisplatin is associated with decreased carnitine. The purpose of this study was to elucidate the effects of one course of induction chemotherapy (IC) for head and neck cancer on blood carnitine levels, focusing on free carnitine (FC). Methods This single-center prospective study investigated 20 patients diagnosed with primary head and neck cancer who underwent IC with cisplatin, docetaxel, and 5-fluorouracil. FC, acylcarnitine (AC), and total… 

References

SHOWING 1-10 OF 29 REFERENCES

Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma

Longitudinal assessments of carnitine and fatigue in patients with hepatocellular carcinoma suggest that lenvatinib affects the Carnitine system in patients undergoing len vatinib therapy and that carnitines insufficiency increases fatigue.

Carnitine Plasma Levels and Fatigue in Children/Adolescents Receiving Cisplatin, Ifosfamide, or Doxorubicin

There was a significant increase in free and total carnitine levels after treatment for patients receiving doxorubicin than patients receiving cisplatin or ifosfamide, and increased fatigue occurred after 1 to 2 courses of chemotherapy.

Serum carnitine levels in patients with tumoral cachexia.

Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia.

Low serum levels of carnitine in terminal neoplastic patients are decreased greatly due to the decreased dietary intake and impaired endogenous synthesis of this substance, which contribute to the progression of cachexia in cancer patients.

Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas

Concomitant antiemetic therapy comprising fosaprepitant, palonosetron, and dexamethasone is effective for head and neck carcinoma.

Nutritional consequences of the radiotherapy of head and neck cancer

The oral and nutritional problems experienced by patients, even prior to therapy, support the idea that nutritional evaluation and maintenance are important not only during therapy, but prior to radiotherapy as well.